Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell
Summary
USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.
What changed
USPTO granted patent US12600954B2 to Allife Medicine (Beijing) Limited, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells using transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG. The methods increase preparation efficiency for these cell types during induced pluripotent stem cell differentiation.
For biotechnology and pharmaceutical companies developing cell-based therapies, this patent grants Allife Medicine exclusive rights to these preparation methods in the United States. Any parties seeking to use or commercialize these methods would need to obtain licensing from the assignee.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for preparing hemogenic endothelium cell and method for preparing hematopoietic stem cell or hematopoietic stem and progenitor cell
Grant US12600954B2 Kind: B2 Apr 14, 2026
Assignee
ALLIFE MEDICINE (BEIJING) LIMITED
Inventors
Rulong Du, Lei Yu, Wenjing Huang, Xuening Wu, Yuchun Gu, Lida Wu
Abstract
A method for preparing hematopoietic endothelial cells and a method for preparing hematopoietic stem cells are provided, comprising inducing hematopoietic mesodermal cells to express transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at specific time periods during the conversion of induced pluripotent stem cells into the hematopoietic endothelial cells or the hematopoietic stem cells. The method can increase the preparation efficiency of at least one of the hematopoietic endothelial cells and the hematopoietic stem cells (including long-term hematopoietic stem cells).
CPC Classifications
C12N 5/0692 C12N 5/0018 C12N 15/86 C07K 14/4702
Filing Date
2025-03-19
Application No.
19083713
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.